摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-[[4-[[2-[2-[5-[[2-[2-[[(4R,4aS,7R,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl]amino]-2-oxoethoxy]acetyl]amino]pentylamino]-2-oxoethoxy]acetyl]amino]-2,6-dimethylphenyl]-piperidin-4-ylidenemethyl]-N,N-diethylbenzamide | 1391034-94-8

中文名称
——
中文别名
——
英文名称
4-[[4-[[2-[2-[5-[[2-[2-[[(4R,4aS,7R,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl]amino]-2-oxoethoxy]acetyl]amino]pentylamino]-2-oxoethoxy]acetyl]amino]-2,6-dimethylphenyl]-piperidin-4-ylidenemethyl]-N,N-diethylbenzamide
英文别名
——
4-[[4-[[2-[2-[5-[[2-[2-[[(4R,4aS,7R,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl]amino]-2-oxoethoxy]acetyl]amino]pentylamino]-2-oxoethoxy]acetyl]amino]-2,6-dimethylphenyl]-piperidin-4-ylidenemethyl]-N,N-diethylbenzamide化学式
CAS
1391034-94-8
化学式
C58H77N7O10
mdl
——
分子量
1032.29
InChiKey
CNKGZZGPSMZTBR-MDADLRLFSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3
  • 重原子数:
    75
  • 可旋转键数:
    23
  • 环数:
    9.0
  • sp3杂化的碳原子比例:
    0.57
  • 拓扑面积:
    220
  • 氢给体数:
    7
  • 氢受体数:
    12

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Tuned-Affinity Bivalent Ligands for the Characterization of Opioid Receptor Heteromers
    作者:Jessica H. Harvey、Darcie H. Long、Pamela M. England、Jennifer L. Whistler
    DOI:10.1021/ml300083p
    日期:2012.8.9
    Opioid receptors, including the mu- and delta-opioid receptors (MOR and DOR), are important targets for the treatment of pain. Although there is mounting evidence that these receptors form heteromers, the functional role of the MOR/DOR heteromer remains unresolved. We have designed and synthesized bivalent ligands as tools to elucidate the functional role of the MOR/DOR heteromer. Our ligands (L2 and L4) are comprised of a compound with low affinity at the DOR tethered to a compound with high affinity at the MOR, with the goal of producing ligands with "tuned affinity" at MOR/DOR heteromers as compared to DOR homomers. Here, we show that both L2 and L4 demonstrate enhanced affinity at MOR/DOR heteromers as compared to DOR homomers, thereby providing unique pharmacological tools to dissect the role of the MOR/DOR heteromer in pain.
查看更多